CD38-deficiency protects from ischemic stroke and ameliorates clinical impairment after tMCAO.

Coronal sections of representative mouse brains were prepared 3 days after tMCAO from wildtype and CD38^−/− mice. Vital tissue stains red after treatment with TTC. Infarct size of CD38^−/− mice was significantly decreased compared to wildtype mice (A). Corresponding to the cerebral infarct size, neurological scores in CD38^−/− mice were significantly lower three days after tMCAO compared to wildtype indicating an attenuated clinical impairment (B) (n = 5–7; *p<0.05 versus).